Core Insights - CNSide Diagnostics, a subsidiary of Plus Therapeutics, presented data on the CNSide CSF Assay Platform, which identifies mutations in cerebrospinal fluid (CSF) for treatment selection in patients with leptomeningeal metastases (LM) [1][2] - The study analyzed 258 CSF samples from 66 LM patients, revealing extensive actionable mutational changes and clinically relevant biomarkers [1][2] Group 1: CNSide CSF Assay Findings - The CNSide CSF Assay evaluated 14 biomarkers, with 12 showing at least one change during treatment [2] - FISH analysis detected biomarker changes in 88% (58/66) of patients, identifying new actionable biomarkers in 26 cases [2] - ICC analysis revealed changes in 20% (13/66) of patients, with new actionable biomarkers identified in 7 cases [2] Group 2: Clinical Implications - The dynamic nature of biomarker mutation profiles in LM provides valuable insights for treatment strategies, highlighting the potential role of radiotherapeutics like Rhenium (186Re) Obisbemeda [2] - The data will be presented at the 2024 Society for NeuroOncology Annual Meeting, emphasizing the implications for differential treatment of LM [2] Group 3: Company Overview - CNSide Diagnostics develops proprietary clinical diagnostic assays to identify tumor cells that have metastasized to the central nervous system, with plans to commercialize the CNSide platform in the U.S. by 2025 [3][4] - Plus Therapeutics focuses on developing targeted radiotherapeutics for difficult-to-treat CNS cancers, with a pipeline that includes recurrent glioblastoma and LM [8]
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases